CTOs on the Move

Phosplatin Therapeutics

www.phosplatin.com

 
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Phosplatin Therapeutics raised $16M on 10/31/2018
Phosplatin Therapeutics raised $18.4M on 08/26/2020

Similar Companies

Viacord

Viacord is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BC Biomedical Laboratories

BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aruna Biomedical

ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Synchem

Synchem, Inc. is a Elk Grove Village, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.